0001214659-26-003166
SEC filingAlzamend Neuro, Inc. reported a net loss of $2.2 million for Q3 2026, consistent with its loss from operations, as the company generated no revenue during the period. Operating expenses totaled $2.2 million, comprising $1.3 million in research and development and $919,000 in general and administrative costs. The company ended the quarter with $2.7 million in cash and total assets of $4.0 million, while total liabilities stood at $1.9 million, resulting in stockholders' equity of $2.2 million. Cash flow from operations was negative $5.3 million, partially offset by $4.0 million in net cash provided by financing activities from stock issuances. The company's basic and diluted net loss per common share was $1.00, based on 3.8 million weighted average common shares outstanding.
Alzamend Neuro, Inc. reported financial results for Q3 2026 ending January 31, 2026. The company recorded a net loss of $2.2 million, which was identical to its loss from operations, indicating no significant other income or expense items beyond the minimal $1,000 interest expense. The company generated no revenue during the period, consistent with its clinical-stage biopharmaceutical focus. Operating expenses totaled $2.2 million, consisting of $1.3 million in research and development costs and $919,000 in general and administrative expenses. The basic and diluted net loss per common share was $1.00, calculated based on 3.8 million weighted average common shares outstanding. No prior period comparisons are provided in the available data.
No revenue was reported for Q3 2026, as Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for neurodegenerative diseases and psychiatric disorders. The company's business model involves research and development activities without commercial product sales at this stage. No segment breakdown, geographic mix, or revenue growth drivers are disclosed in the provided financial data, as the company has not yet generated revenue from product sales or licensing agreements.
With no revenue generated during Q3 2026, traditional margin calculations (gross margin, operating margin) are not applicable. The company's cost structure is dominated by operating expenses totaling $2.2 million, with research and development representing approximately 59% of total operating expenses ($1.3 million) and general and administrative expenses comprising the remaining 41% ($919,000). The net loss margin, calculated as net loss divided by revenue, cannot be determined due to zero revenue. The company's accumulated deficit increased to $64.4 million, reflecting ongoing investment in research and development activities without corresponding revenue generation.
Cash flow from operating activities was negative $5.3 million for the period, primarily driven by the net loss of $5.9 million, partially offset by non-cash adjustments including depreciation ($83K), stock-based compensation ($84K), and changes in working capital. Investing activities used $90,000 for equipment purchases. Financing activities provided $4.0 million in net cash, consisting of $1.9 million from common stock issuance and $4.0 million from preferred stock issuance. The net decrease in cash was $1.2 million, resulting in an ending cash balance of $3.9 million. The balance sheet shows total assets of $4.0 million, including $2.7 million in cash and $986,000 in prepaid expenses. Total liabilities of $1.9 million are entirely current, consisting of accounts payable and accrued liabilities. Stockholders' equity stands at $2.2 million.
No specific management guidance, strategic priorities, or forward-looking statements are provided in the available financial data. As a clinical-stage company, Alzamend Neuro's future performance will depend on the success of its research and development programs, regulatory approvals, and ability to secure additional funding. The company's cash position of $2.7 million, combined with the $4.0 million raised from financing activities during the quarter, suggests ongoing capital needs for research and development activities. No specific risk factors or strategic initiatives are disclosed in the provided financial statements.